AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02148679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DASH/SRD
Description: Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
Study NCT02148679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH/SRD
Description: Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
Study NCT02148679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
Study NCT00794976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Iontophoretic Patch (low dose)
Study NCT00794976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Iontophoretic Patch (high dose)
Study NCT00794976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Passive Patch
Study NCT00794976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study NCT02599259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitored (M+)
Description: Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
Study NCT03486054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT
Description: The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
Study NCT03486054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
Study NCT02697773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
Study NCT02697773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Description: Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
Study NCT02697773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg/5mg
Description: Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
Study NCT01138111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
Study NCT04576182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-expressive treatment
Description: Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
Study NCT04576182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions-Focused treatment
Description: Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
Study NCT04764955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
Study NCT04764955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
Study NCT04764955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
Study NCT03047850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of Delta Down and Delta Pulse Pressure
Description: Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
Study NCT02405663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual removal
Description: one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
Study NCT02405663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord traction
Description: one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
Study NCT03122340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropren
Description: Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
Study NCT02189889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPO
Description: The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
Study NCT02189889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Feraheme
Description: Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
Study NCT03122340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oil
Description: Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
Study NCT01427842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEVINE vancomycin regimen
Description: The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
Study NCT04061642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Decision Aid
Description: The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
Study NCT01045993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Device
Description: 8-Hour Heatwrap
Study NCT01045993 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Inactive wrap worn for 8 hours
Study NCT01045993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed analgesic
Description: 2 x 200 mg ibuprofen tablets
Study NCT01045993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo tablets
Study NCT03898830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eon™ FR 1064 nm device
Description: The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
Study NCT02381626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA air purifier
Description: air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
Study NCT02381626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02381626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Log-book
Description: PM and biological measurements
Study NCT00954317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural placed low
Description: epidural placed low
Study NCT00954317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high epidural
Description: high epidural
Study NCT00922350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELIOX
Description: The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
Study NCT00922350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OXYGEN
Description: The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
Study NCT00922350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELIOX+POSTURE
Description: Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th .
Study NCT00922350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OXYGEN + POSTURE
Description: The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
Study NCT04722484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Study NCT01107405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (QD)
Description: Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
Study NCT01107405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (BID)
Description: Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
Study NCT01107405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate base (QID)
Description: Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
Study NCT01107405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate suspension
Description: Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
Study NCT01107405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of loteprednol etabonate
Description: Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
Study NCT00589979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm (Lidocaine 5% Patch)
Description: Topical Patch
Study NCT00589979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Topical Patch
Study NCT02957149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma
Description: Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
Study NCT02957149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Concentrated Platelet Rich Plasma System
Study NCT04528589 — intervention group
Intervention type: OTHER
Intervention: prenatal psychotherapy
Description: Prenatal psychotherapy to break intergenerational risk of adverse childhood events
Study NCT02639390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Therapy
Description: Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
Study NCT02639390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
Study NCT02639390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
Study NCT04095065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters
Description: Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
Study NCT04095065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters and itMatters Sexual Violence Prevention
Description: Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
Study NCT04095065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters Well-being and itMatters Sexual Violence Prevention
Description: Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
Study NCT04095065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: itMatters Well-being
Description: Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
Study NCT01469039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072
Description: Intramuscular (IM) injection, 441 mg or 882 mg given monthly
Study NCT01469039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IM injection, given monthly
Study NCT00698828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Twice daily subcutaneous injections of placebo for 12 weeks.
Study NCT00698828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN11031 20 μg/kg
Description: Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
Study NCT00698828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN11031 40 μg/kg
Description: Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
Study NCT02833883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02833883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-115
Study NCT00705705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network leader training
Description: Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
Study NCT00705705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HIV risk-reduction counseling
Description: Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
Study NCT00705705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV risk-reduction counseling
Description: Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
Study NCT00693121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine hydrochloride
Description: 100mg administered orally twice daily x 14 days
Study NCT00693121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg intravenous (IV) over 30-60 min on Day 1
Study NCT03050814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-CEA vaccine
Description: Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
Study NCT03870256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: Patient receive 600mic gm sublingual misoprostol
Study NCT03870256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient receive 100 mic gm carbetocin IV
Study NCT03870256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: The patient receives 1gm oral tranexamic acid
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
Study NCT03346525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular benzathine penicillin G (BPG) prophylaxis
Description: Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
Study NCT02731287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks